We are able to recruit even rare trial populations fast and reliably.Our database is exclusive to people actively seeking to take part in clinical trials. This is a significant improvement over most databases of patients as these contain a majority of patients who are reluctant to participate in a clinical study.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
